Clinical Trials Directory

Trials / Completed

CompletedNCT01227499

Differential Diagnosis of STA-PSV in Thyrotoxicosis

Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease

Status
Completed
Phase
Study type
Observational
Enrollment
169 (actual)
Sponsor
xiaolong zhao · Academic / Other
Sex
All
Age
15 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Aim: Graves's disease and thyroiditis can both characterized with thyrotoxicosis, but their clinical outcome and therapy is quiet different. Measurement of iodine uptake is the gold standard to differential diagnosis the thyroiditis or Graves's disease. But the iodine uptake is limited for its availability in china and easily influenced by medicine or food contained iodine.The blood pattern of thyroid CFDS is useful for differentiate the cause of thyrotoxicosis.Most previous studies using the descriptive pattern of thyroid CFDS is easily varied by operator subjective judgement. This study is focus on the role of peak systolic velocity of thyroid superior artery in differential diagnosis of thyrotoxicosis. Methods: Patients with thyrotoxicosis symptoms without recent medicine history were enrolled in two clinical center. Its thyroid function, iodine uptake , CFDS of thyroid and peak systolic velocity of thyroid superior artery is detected. Thyrotoxicosis is defined as TSH level below the low value of normal range. Graves disease is defined as the typical symptoms of graves disease such as graves ophthalmopathy or increased iodine uptake. Thyroiditis is defined as lack of typical symptoms of graves disease or decreased iodine uptake.We use receiver operator curve(ROC) to evaluate its diagnosis value

Conditions

Timeline

Start date
2010-06-01
Primary completion
2011-11-01
Completion
2011-11-01
First posted
2010-10-25
Last updated
2014-05-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01227499. Inclusion in this directory is not an endorsement.